HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:

Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate

This article was originally published in The Rose Sheet

  • News
  • The Rose Sheet

Executive Summary

Ongoing studies on Bristol-Myers Squibb's newly approved Vaniqa prescription hair removal drug could broaden the target consumer of the topical cream to include men. FDA approved the product for removal of women's facial hair July 27.

You may also be interested in...



OTC Vaniqa Could Surface By Early 2005

Women First HealthCare may explore Rx-to-OTC switch opportunities forVaniqa facial hair growth retardation cream as early as 2004, the firm stated

OTC Vaniqa Could Surface By Early 2005

Women First HealthCare may explore Rx-to-OTC switch opportunities forVaniqa facial hair growth retardation cream as early as 2004, the firm stated

Vaniqa

Second round of national TV ads launching now and print ads debuting in April focus on educating women who remove unwanted facial hair rather than building brand awareness as the first campaign did, Bristol Myers Squibb said during Feb. 22 press event. Co-marketed by Gillette, Rx topical cream (13.9% eflornithine) debuted in September (1"The Rose Sheet" Aug. 7, 2000, p. 6). Second round of ads will feature close-up shots of women applying the cream and an illustration of how product effects the hair follicle
Table

View full table

Related Content

HBW Insight HBW Insight HBW Insight HBW Insight
Tags:
UsernamePublicRestriction

Register

RS008300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By